Molecular Profiling Is Rather Likely to Be Cost Effective

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)
61 Downloads (Pure)

Abstract

In a recent report, Bonastre et al1 calculated the cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer and concluded that, under the present circumstances in France, the 70-gene signature (MammaPrint) is unlikely to be cost effective.
Original languageEnglish
Pages (from-to)1626-1627
JournalJournal of clinical oncology
Volume33
Issue number14
DOIs
Publication statusPublished - 2015

Keywords

  • METIS-311885
  • IR-97319

Fingerprint Dive into the research topics of 'Molecular Profiling Is Rather Likely to Be Cost Effective'. Together they form a unique fingerprint.

Cite this